Latest and emerging therapies for primary biliary cirrhosis and primary sclerosing cholangitis

Current Gastroenterology Reports

Volumn 12, Issue 1, 2010, Pages 13-22

  Zein, Claudia O ^a   Lindor, Keith D ^a  

^a MAYO CLINIC   (United States)

Author keywords

Primary biliary cirrhosis; Primary sclerosing cholangitis; Therapy

Indexed keywords

6ALPHA ETHYL CHENODEOXYCHOLIC ACID; AZATHIOPRINE; BEZAFIBRATE; CHENODEOXYCHOLIC ACID DERIVATIVE; CHLORAMBUCIL; COLESTYRAMINE; CORTICOSTEROID; CYCLOSPORIN; ETANERCEPT; FENOFIBRATE; FIBRIC ACID DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LAMIVUDINE; METHOTREXATE; METRONIDAZOLE; MINOCYCLINE; MODAFINIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENICILLAMINE; PENTOXIFYLLINE; PLACEBO; RIFAMPICIN; RITUXIMAB; SERTRALINE; SILYMARIN; TACROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; URSODEOXYCHOLIC ACID; VITAMIN D; ZIDOVUDINE;

ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE HEPATITIS; BILE DUCT CARCINOMA; BILE DUCT OBSTRUCTION; BLOATING; CLINICAL FEATURE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; ENDOSCOPIC THERAPY; EVIDENCE BASED MEDICINE; FATIGUE; FATTY LIVER; GENETIC PREDISPOSITION; HUMAN; IMMUNOGLOBULIN G DEFICIENCY; INTRAHEPATIC CHOLESTASIS; LABORATORY TEST; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MORBIDITY; NONHUMAN; OPTIMAL DRUG DOSE; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PLASMAPHERESIS; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PRURITUS; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; VITAMIN DEFICIENCY;

ADULT; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; CLINICAL PROTOCOLS; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER CIRRHOSIS, BILIARY; URSODEOXYCHOLIC ACID;

EID: 77950863027     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-009-0079-2     Document Type: Review

References (78)

1. MM Kaplan ME Gershwin 2005 Primary biliary cirrhosis N Engl J Med 353 1261 1274 10.1056/NEJMra043898 16177252 1:CAS:528:DC%2BD2MXhtVeltLbI (Pubitemid 41345948)
2. MI Prince OF James 2003 The epidemiology of primary biliary cirrhosis Clin Liver Dis 7 795 819 10.1016/S1089-3261(03)00102-8 14594132 (Pubitemid 37229505)
3. ME Gershwin C Selmi HJ Worman, et al. 2005 Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients Hepatology 42 1194 1202 10.1002/hep.20907 16250040 (Pubitemid 43112687)
4. H Kita S Matsumura XS He, et al. 2002 Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis J Clin Invest 109 1231 1240 11994412 1:CAS:528: DC%2BD38XjsFalsbw%3D
5. M Prince A Chetwynd W Newman, et al. 2002 Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years Gastroenterology 123 1044 1051 10.1053/gast.2002.36027 12360466
6. CO Zein P Angulo KD Lindor 2003 When is liver biopsy needed in the diagnosis of primary biliary cirrhosis Clin Gastroenterol Hepatol 1 89 95 10.1053/cgh.2003.50014 15017500 (Pubitemid 37248079)
7. KD Lindor ME Gershwin R Poupon, et al. 2009 AASLD practice guidelines. Primary biliary cirrhosis Hepatology 50 291 308 10.1002/hep.22906 19554543 These guidelines are an excellent review of crucial published data and recommendations for the evaluation and management of patients with PBC.
8. P Angulo ER Dickson TM Therneau, et al. 1999 Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial J Hepatol 30 830 835 10.1016/S0168-8278(99)80136-6 10365809 1:CAS:528:DyaK1MXjtlKntLY%3D (Pubitemid 29248983)
9. KD Lindor TM Therneau RA Jorgensen, et al. 1996 Effects of ursodeoxycholic acid on survival in patients with primary biliary cirrhosis Gastroenterology 110 1515 1518 10.1053/gast.1996.v110.pm8613058 8613058 1:CAS:528:DyaK28XjtV2htLc%3D (Pubitemid 26134085)
10. KD Lindor ER Dickson WP Baldus, et al. 1994 Ursodeoxycholic acid in the treatment of primary biliary cirrhosis Gastroenterology 106 1284 1290 8174890 1:STN:280:DyaK2c3ivFCluw%3D%3D
11. EJ Heathcote K Cauch-Dukek V Walker, et al. 1994 The Canadian multicenter double-blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 19 1149 1156 10.1002/hep.1840190512 8175136 1:STN:280:DyaK2c3ivFOntQ%3D%3D
12. T Pasha J Heathcote S Gabriel, et al. 1999 Cost-effectiveness of ursodeoxycholic acid therapy in primary biliary cirrhosis Hepatology 29 21 26 10.1002/hep.510290116 9862844 1:STN:280:DyaK1M%2FotFKktg%3D%3D (Pubitemid 29023980)
13. B Combes RL Carithers Jr WC Maddrey, et al. 1995 A randomized, double blind, placebo controlled trial of ursodeoxycholic acid in primary biliary cirrhosis Hepatology 22 759 766 7657280 1:CAS:528:DyaK2MXoslartbs%3D
14. B Combes VA Luketic MG Peters, et al. 2004 Prolonged follow-up of patients in the US multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis Am J Gastroenterol 99 264 268 10.1111/j.1572-0241.2004.04047.x 15046215 1:CAS:528:DC%2BD2cXitleisLg%3D (Pubitemid 38279867)
15. Poupon RE, Balkau B, Eschwège E, et al.: A multicenter, controlled trial of ursodiol for treatment of primary biliary cirrhosis. UDCA-PBC study group. N Engl J Med 1991, 324: 1548-1554.
16. Poupon RE, Poupon R, Balkau B: Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC study group. N Engl J Med 1994, 330:1342-1347.
17. A Pares L Caballeria J Rodes, et al. 2000 Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver J Hepatology 32 561 566 10.1016/S0168-8278(00)80216-0 1:CAS:528:DC%2BD3cXisFOjsbg%3D (Pubitemid 30180374)
18. A Pares L Caballeria J Rodes 2006 Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 715 720 10.1053/j.gastro.2005.12.029 16530513 1:CAS:528:DC%2BD28XjsVylsbg%3D (Pubitemid 43374522)
19. RA Jorgensen ER Dickson AF Hoffman, et al. 1995 Characterization of patients with a complete biochemical response to ursodeoxycholic acid Gut 36 935 938 10.1136/gut.36.6.935 7615288 1:STN:280:DyaK2MzktVajsg%3D%3D
20. C Corpechot L Abenavoli N Rabahi, et al. 2008 Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis Hepatology 48 871 877 10.1002/hep.22428 18752324 1:CAS:528:DC%2BD1cXhtFKrsLfN This article presents important results regarding the biochemical response to UDCA as a predictor of survival in patients with PBC.
21. • Kuiper EM, Hansen BE, deVries RA, et al.: Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136:1281-1287. This article discusses the largest study assessing the best predictors of survival of PBC patients based on biochemical response to UDCA therapy.
22. RE Poupon AM Bonnand Y Chretien, et al. 1999 Ten-year survival in ursodeoxycholic acid treated patients with primary biliary cirrhosis. The UDCA-PBC study group Hepatology 29 1668 1671 10.1002/hep.510290603 10347106 1:CAS:528:DyaK1MXjvFOms7k%3D (Pubitemid 29247037)
23. K Dohmen T Mizuta M Nakamuta, et al. 2004 Fenofibrate for patients with asymptomatic primary biliary cirrosis World J Gastroenterol 10 894 898 15040040 1:CAS:528:DC%2BD2cXjtl2hu74%3D
24. Mason AL, Lindor KD, Bacon BR, et al.: Randomized controlled trial of zidovudine and lamivudine in patients with primary biliary cirrhosis stabilized on ursodiol. Aliment Pharmacol Ther 2008 (Epub ahead of print).
25. RP Myers AA Shaheen MG Swain, et al. 2007 Rituximab for primary biliary cirrhosis (PBC) refractory to ursodeoxycholic acid (UDCA) Hepatology 46 550A
26. R Poupon O Chazouilleres C Corpechot, et al. 2006 Development of autoimmune hepatitis in typical primary biliary cirrhosis Hepatology 44 85 90 10.1002/hep.21229 16799997 (Pubitemid 44049141)
27. MG Silveira JA Talwalkar P Angulo, et al. 2007 Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes Am J Gastroenterol 102 1244 1250 10.1111/j.1572-0241.2007.01136.x 17319931 (Pubitemid 46802005)
28. O Chazouilleres D Wendum L Serfaty, et al. 2006 Long-term outcome and response to therapy of primary biliary cirrhosis-autoimmune hepatitis overlap syndrome J Hepatol 44 400 406 10.1016/j.jhep.2005.10.017 16356577 1:CAS:528:DC%2BD28XksVSjtA%3D%3D (Pubitemid 43069223)
29. NF LaRusso BL Shneider D Black, et al. 2006 Primary sclerosing cholangitis: summary of a workshop Hepatology 44 746 764 10.1002/hep.21337 16941705 (Pubitemid 44433732)
30. A Bergquist G Lindberg S Saarinen, et al. 2005 Increased prevalence of primary sclerosing cholangitis among first degree relatives J Hepatol 42 252 256 10.1016/j.jhep.2004.10.011 15664252 (Pubitemid 40143473)
31. CA Aoki CL Bowlus ME Gershwin 2005 The immunobiology of primary sclerosing cholangitis Autoimmun Rev 4 137 143 10.1016/j.autrev.2004.09.003 15823499 1:CAS:528:DC%2BD2MXkvFOquro%3D (Pubitemid 40488742)
32. JR Hov KM Boberg TH Karlsen 2008 Autoantibodies in primary sclerosing cholangitis World J Gastroenterol 14 3781 3791 10.3748/wjg.14.3781 18609700 1:CAS:528:DC%2BD1cXht1WlsrvI
33. AE Berstad L Aabakken HJ Smith, et al. 2006 Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis Clin Gastroenterol Hepatol 4 514 520 10.1016/j.cgh.2005. 10.007 16616358
34. E Bjornsson 2009 Small-duct primary sclerosing cholangitis Curr Gastroenterol Rep 11 37 41 10.1007/s11894-009-0006-6 19166657
35. Lindor KD: Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997, 336:691-695.
36. D Rost G Rudolph P Kloeters-Plachky, et al. 2004 Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis Hepatology 40 693 698 10.1002/hep.20370 15349909 1:CAS:528:DC%2BD2cXot1OrtLc%3D (Pubitemid 39265592)
37. SA Mitchell DS Bansi N Hunt, et al. 2001 A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis Gastroenterology 121 900 907 10.1053/gast.2001.27965 11606503 1:CAS:528:DC%2BD3MXnvVynur4%3D
38. Olsson R, Boberg KM, deMuckadell OS, et al.: High-dose ursodeoxycholic acid in primary sclerosing cholangitis: a 5-year multicenter, randomized, controlled study. Gastroenterology 2005, 129:1464-1472.
39. DM Harnois P Angulo RA Jorgensen, et al. 2001 High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis Am J Gastroenterol 96 1558 1562 10.1111/j.1572-0241.2001.03777.x 11374699 1:STN:280:DC%2BD3M3ptF2jsA%3D%3D
40. SN Cullen C Rust K Fleming, et al. 2008 High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective J Hepatol 48 792 800 10.1016/j.jhep.2007.12.023 18314215 1:CAS:528: DC%2BD1cXktVGrurw%3D
41. KD Lindor FB Enders JA Schmoll, et al. 2009 Randomized, double blind controlled trial of high dose ursodeoxycholic acid for primary sclerosing cholangitis Hepatology 50 671 673 10.1002/hep.23174 1:CAS:528:DC%2BD1MXhtFKntL7M The results of this randomized controlled trial support the conclusion that high-dose UDCA at 28 to 30 mg/kd/d should not be used in patients with PSC given the lack of survival benefits and higher risk of adverse events.
42. DS Pardi EV Loftus WK Kremers, et al. 2003 Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 889 893 10.1053/gast.2003.50156 12671884 1:CAS:528:DC%2BD3sXjsFOjurY%3D (Pubitemid 36389790)
43. JA Talwalkar AA Gossard JC Keach, et al. 2007 Tacrolimus for the treatment of primary sclerosing cholangitis Liver Int 27 451 453 10.1111/j.1478-3231.2007.01441.x 17403184 1:CAS:528:DC%2BD2sXlvFyksLk%3D (Pubitemid 46534566)
44. M Farkkila AL Karvonen H Nurmi, et al. 2004 Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial Hepatology 40 1379 1386 10.1002/hep.20457 15565569 1:CAS:528:DC%2BD2MXhslagtg%3D%3D (Pubitemid 39657012)
45. MG Silveria NJ Torok AA Gossard, et al. 2009 Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study Am J Gastroenterol 104 83 88 10.1038/ajg.2008.14 1:CAS:528:DC%2BD1MXht1Sgtw%3D%3D
46. P Angulo RA Jorgensen KV Kowdley, et al. 2008 Silymarin in the treatment of patients with primary sclerosing cholangitis: an open label pilot study Dig Dis Sci 53 1716 1720 10.1007/s10620-007-0052-6 17940903 1:CAS:528: DC%2BD1cXlt1Siu7g%3D (Pubitemid 351624429)
47. R Kita S Takamatsu T Kimura, et al. 2006 Bezafibrate may attenuate biliary damage associated with chronic liver diseases accompanied by high serum biliary enzyme levels J Gastroenterol 41 686 692 10.1007/s00535-006-1831-0 16933007 1:CAS:528:DC%2BD28XosFWrt7s%3D (Pubitemid 44288534)
48. L Gheorge S Iacob C Gheorghe, et al. 2004 Frequency and predictive factors for overlap syndrome between autoimmune hepatitis and primary cholestatic liver disease Eur J Gastroenterol Hepatol 16 585 592 10.1097/00042737-200406000-00012 (Pubitemid 38703867)
49. A Floreani ER Rizzotto F Ferrara, et al. 2005 Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome Am J Gastroenterol 100 1516 1522 10.1111/j.1572-0241.2005.41841.x 15984974 (Pubitemid 41032356)
50. E Bjornsson R Olsson A Bergquist, et al. 2008 The natural history of small-duct primary sclerosing cholangitis Gastroenterology 134 975 980 10.1053/j.gastro.2008.01.042 18395078 (Pubitemid 351451987)
51. P Charatcharoenwitthaya P Angulo FB Enders, et al. 2008 Impact of inflammatory bowel disease and ursodeoxycholic acid therapy of small duct primary sclerosing cholangitis Hepatology 47 133 142 10.1002/hep.21960 17992695 1:CAS:528:DC%2BD1cXhtlChsrc%3D (Pubitemid 351171050)
52. A Ghazale ST Chari L Zhang, et al. 2008 Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy Gastroenterology 134 706 715 18222442
53. FD Mendes R Jorgensen J Keach, et al. 2006 Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis Am J Gastroenterol 101 2070 2075 10.1111/j.1572-0241.2006.00772.x 16879434 1:CAS:528: DC%2BD28XhtVyisLzK (Pubitemid 44337633)
54. K Burak P Angulo T Pasha, et al. 2004 Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis Am J Gastroenterol 99 523 526 10.1111/j.1572-0241.2004.04067.x 15056096 (Pubitemid 38524134)
55. C Levy J Lymp P Angulo, et al. 2005 The value of CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis Dig Dis Sci 50 1734 1740 10.1007/s10620-005-2927-8 16133981 1:CAS:528:DC%2BD2MXovVKksb4%3D (Pubitemid 41203674)
56. P Charatcharoenwithaya FB Enders KC Halling, et al. 2008 Utility of serum markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis Hepatology 48 1106 1117 10.1002/hep.22441 1:CAS:528:DC%2BD1cXht1Khu77K
57. DJ Rea JK Hemback CB Rosen, et al. 2005 Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma Ann Surg 242 451 458 16135931
58. JS Newton GJ Gibson M Tomlinson, et al. 2006 Fatigue in primary biliary cirrhosis is associated with excessive daytime somnolence Hepatology 44 91 98 10.1002/hep.21230 16800007 (Pubitemid 44049142)
59. DE Jones JL Newton 2007 An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis Aliment Pharmacol Ther 25 471 476 17270003 1:CAS:528:DC%2BD2sXjs1Glu7s%3D
60. Ian Gan S, de Jongh M, Kaplan MM: Modafinil in the treatment of debilitating fatigue in primary biliary cirrhosis: a clinical experience. Dig Dis Sci 2009, 54:2242-2246.
61. S Khurana P Singh 2006 Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized controlled trials Liver Int 26 943 948 10.1111/j.1478-3231.2006.01326.x 16953834 1:CAS:528:DC%2BD28XhtF2qsbzK (Pubitemid 44323412)
62. MJ Mayo I Handem S Saldana, et al. 2007 Sertraline as a first-line treatment for cholestatic pruritus Hepatology 45 666 674 10.1002/hep.21553 17326161 1:CAS:528:DC%2BD2sXjs1GkurY%3D (Pubitemid 46450618)
63. P Tandon BH Rowe B Vandermeer 2007 The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus Am J Gastroenterol 102 1528 1536 10.1111/j.1572-0241.2007.01200.x 17403073 1:CAS:528:DC%2BD2sXoslGltLg%3D (Pubitemid 46976283)
64. MP Epstein MM Kaplan 2004 A pilot study of etanercept in the treatment of primary sclerosing cholangitis Dig Dis Sci 49 1 4 10.1023/B:DDAS.0000011827. 87103.2e 14992426 1:CAS:528:DC%2BD2cXislentw%3D%3D (Pubitemid 38183736)
65. A Pares L Cisneros JM Salmeron, et al. 2004 Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis Am J Gastroenterol 99 1105 1110 10.1111/j.1572-0241.2004.30204.x 15180733 (Pubitemid 38917816)
66. T Pusl GU Denk KG Parhofer, et al. 2006 Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis J Hepatol 45 887 891 10.1016/j.jhep.2006.08.008 17046095 1:CAS:528: DC%2BD28XhtFeqtLvJ (Pubitemid 44646686)
67. KV Menon P Angulo S Weston, et al. 2001 Bone disease in primary biliary cirrhosis: independent indicators and rate of progression J Hepatol 35 316 323 10.1016/S0168-8278(01)00144-1 11592591 1:STN:280:DC%2BD3MrksFCgug%3D%3D (Pubitemid 32844184)
68. P Angulo TM Therneau A Jorgensen, et al. 1998 Bone disease in patients with primary sclerosing cholangitis: prevalence, severity, and prediction of progression J Hepatol 29 729 735 10.1016/S0168-8278(98)80253-5 9833910 1:STN:280:DyaK1M%2FkvFKmtA%3D%3D (Pubitemid 28505929)
69. European Association for the Study of the Liver 2009 EASL clinical practice guidelines: management of cholestatic liver diseases J Hepatol 51 237 267 10.1016/j.jhep.2009.04.009
70. CO Zein RA Jorgensen B Clarke, et al. 2005 Alendronate improves bone mineral density in primary biliary cirrhosis: a randomized placebo-controlled trial Hepatology 42 762 771 10.1002/hep.20866 16175618 1:CAS:528: DC%2BD2MXhtFGlsbjJ (Pubitemid 41401113)
71. RA Jorgensen KD Lindor JS Sartin, et al. 1995 Serum lipid and fat-soluble vitamin levels in primary sclerosing cholangitis J Clin Gastroenterol 20 215 219 10.1097/00004836-199504000-00011 7797830 1:STN:280:DyaK2MzhvVCnsg%3D%3D
72. JR Phillips P Angulo T Petterson, et al. 2001 Fat-soluble vitamin levels in patients with primary biliary cirrhosis Am J Gastroenterol 96 2745 2750 10.1111/j.1572-0241.2001.04134.x 11569705 1:CAS:528:DC%2BD3MXns1ygsLc%3D
73. J Bruix M Sherman 2005 Practice Guidelines Committee, American Association for the Study of Liver Diseases: Management of hepatocellular carcinoma Hepatology 42 1208 1236 10.1002/hep.20933 16250051 (Pubitemid 43112690)
74. G Garcia-Tsao AJ Sanya ND Grace, et al. 2007 Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis Hepatology 46 922 938 10.1002/hep.21907 17879356 1:CAS:528:DC%2BD2sXhtFWhsrjF (Pubitemid 47436138)
75. CO Zein P Angulo KD Lindor 2004 Prevalence and predictors of esophageal varices in primary sclerosing cholangitis Hepatology 39 204 210 10.1002/hep.20029 14752839 (Pubitemid 38461483)
76. P Angulo KD Lindor TM Therneau, et al. 1999 Utilization of the Mayo Risk Score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid Liver 19 115 121 10.1111/j.1478-3231.1999.tb00020.x 10220741 1:STN:280:DyaK1M3jslSqsg%3D%3D
77. C Levy CO Zein J Gomez, et al. 2007 Prevalence and predictors of esophageal varices in patients with primary biliary cirrhosis Clin Gastroenterol Hepatol 5 803 808 10.1016/j.cgh.2007.02.031 17544879 (Pubitemid 47031056)
78. B Bessler R Pinto D El-Ashry, et al. 2005 Which patients with primary biliary cirrhosis or primary sclerosing cholangitis should undergo endoscopic screening for esophageal varices detection? Gut 54 407 410 10.1136/gut.2004. 040832 (Pubitemid 40299099)